Skip to content

Journal · Pharmaceutical technology · Updated 21 November 2026

AAPS PharmSciTech

Read AAPS PharmSciTech articles on DeepDyve. No university library needed.

AAPS PharmSciTech has published since 2000 and covers pharmaceutical technology, from designing and testing drug formulations to delivery systems such as nanocarriers and microneedles. It’s an official journal of the American Association of Pharmaceutical Scientists, published by Springer Nature. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of AAPS PharmSciTech
Journal cover

AAPS PharmSciTech at a glance

Full title
AAPS PharmSciTech
Abbreviation (NLM)
AAPS PharmSciTech
Publisher
Springer Nature
ISSN (online only)
1530-9932
First published
2000
Subjects
Pharmacology
Access model
Hybrid (33% free to read in 2026)

Ways to access AAPS PharmSciTech

33% of the articles AAPS PharmSciTech published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 33% of AAPS PharmSciTech articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to AAPS PharmSciTech. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read AAPS PharmSciTech articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

AAPS PharmSciTech’s 2025 Journal Impact Factor is 5.1, and its 5-year Impact Factor is 4.4.

5.1

Journal Impact Factor (2025)

4.4

5-year Impact Factor (2025)

1.5M

Downloads (2025)

Source: journal metrics on the AAPS PharmSciTech homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent AAPS PharmSciTech research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. Open accessOtomycosis · Drug delivery

    Harnessing Novel Tetra-Synergistic Bilosomes for Effective Otomycosis Management: Integrated In-Vitro, Microbiological and In-vivo Studies

    Developing a topical treatment for otomycosis, the authors report that bilosomes carrying the antifungal voriconazole eradicated fungal growth in 33% less time than a voriconazole suspension and gave a 2.18-fold permeation enhancement ratio, with no tissue damage.

    Fahmy et al. · AAPS PharmSciTech, published online February 19, 2026 · DOI 10.1208/s12249-026-03342-5

  2. LitStreamNanomedicine · Quality by design

    Implementing QbD for Nano-Pharmaceuticals and Complex Formulations to Achieve Predictable and High-Quality Outcomes

    Panwar and colleagues review how artificial intelligence and machine learning can be combined with the Quality by Design framework in developing nanopharmaceuticals, covering data workflows, regulatory perspectives, current applications and remaining challenges.

    Panwar et al. · AAPS PharmSciTech, published online January 9, 2026 · DOI 10.1208/s12249-025-03308-z

  3. LitStreamLiposomes · Drug delivery

    Liposome-Based Drug Delivery Systems: Mechanisms, Preparation Strategies, Clinical Status, and Therapeutic Applications

    Shadab and colleagues review liposome-based drug delivery, from mechanisms and preparation technologies such as microfluidics to clinically established formulations like Doxil and AmBisome, along with targeted liposomes, RNA-delivery platforms and hybrid lipid–polymer vesicles.

    Shadab et al. · AAPS PharmSciTech, published online April 23, 2026 · DOI 10.1208/s12249-026-03425-3

  4. LitStreamNanoparticles · Clinical translation

    Recent Trends in the Development and Clinical Translation of Polymer-based Targeted Therapeutic Nanoparticle

    Singh and colleagues review polymeric nanoparticles for targeted drug delivery, including polymer–metal theranostics and AI-driven design, and note that failures in clinical translation are usually linked to inadequate physicochemical characterisation, safety issues and vague regulatory pathways.

    Singh et al. · AAPS PharmSciTech, published online February 4, 2026 · DOI 10.1208/s12249-025-03319-w

  5. LitStreamNatural polymers · Machine learning

    AI-enabled, QbD-aligned Predictive, and Sustainable Design of Natural Polymer-based Drug Delivery Systems

    Suksaeree and colleagues review how artificial intelligence and machine learning, used under quality by design, can model drug delivery systems made from natural polymers such as chitosan, alginate and silk fibroin, and list remaining challenges in dataset standardization, model transparency and regulatory validation.

    Suksaeree et al. · AAPS PharmSciTech, published online January 29, 2026 · DOI 10.1208/s12249-026-03326-5

See every AAPS PharmSciTech article on DeepDyve

Questions about AAPS PharmSciTech

How can I read AAPS PharmSciTech articles without a subscription?

33% of AAPS PharmSciTech articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read AAPS PharmSciTech articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for AAPS PharmSciTech?

AAPS PharmSciTech isn’t abbreviated: its NLM (PubMed) abbreviation is simply AAPS PharmSciTech.

What is the ISSN of AAPS PharmSciTech?

AAPS PharmSciTech is published online only; its ISSN is 1530-9932.

What is the impact factor of AAPS PharmSciTech?

AAPS PharmSciTech’s Journal Impact Factor is 5.1 (2025), and its 5-year Impact Factor is 4.4, according to Springer Nature’s published metrics.

Is AAPS PharmSciTech open access?

AAPS PharmSciTech is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 96 of 288 AAPS PharmSciTech articles (33%) carry a Creative Commons license, per Crossref.

AAPS PharmSciTech articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading AAPS PharmSciTech today

One month free, then less than $2 a day. AAPS PharmSciTech, plus millions of articles from thousands of journals.

Start free month

Like this: